Market Overview

UPDATE: Dawson James Initiates Pharmacyclics at Market Outperform on Ibrutinib Confidence

Related PCYC
Target Expected To Be Right On Target With Earnings
Pharmacyclics Appoints Chief Commercial Officer

Dawson James initiated coverage on Pharmacyclics (NASDAQ: PCYC) with a Market Outperform rating and a $101 price target.

Dawson James commented, "Ibrutinib – a novel Btk inhibitor - represents the most exciting compound in the field of the multi-billion dollar market for B-cell related malignancies. Ibrutinib is, by far, the leader in this therapeutic category, easily has blockbuster potential and, based upon our analysis, is likely to elevate PCYC valuation to the very top-tier of biotech stocks. We believe the upcoming American Society Hematology meeting (ASH, December 7-12, Atlanta, GA) will further differentiate ibrutinib from any potential competitors."

Pharmacyclics closed at $55.01 on Thursday.

Posted-In: Dawson JamesAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (PCYC)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters